Skyland Bio's innovative all-human monoclonal antibody TJC4 obtains FDA clinical trial license
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Skyland Biotech (Shanghai) LimitedCompany(http://("Skyland Bio") announced that its self-developed innovative all-human monoclonal antibody TJC4 for CD47 targets was licensed by the u.SFoodDrug(http://Administration (http://
)Administration (
FDA)on January 25, 2019, theof clinical testing(http:// for cancer researchTJC4
TJC4 is the third candidatedrug (http:// approved by fda clinical trials within one month, an important step in bringing new drug (http:// with the best potential of its kind to patients around the world Unlike other known CD47 antibodies, TJC4 has a unique binding epitope that binds to red blood cells to a minimum, has no coagulation, and has no anemia symptoms in crab-eating monkey toxicology experiments in addition , TJC4 is effective in both monotherapy and combination therapy in animal models for malignant blood tumors and solid tumors Following the approval of clinical trials, Skyfall Bio will fully launch 1/1b clinical trials to assess tJC4's safety, tolerance and efficacy in patients with solid and lymphoma in monotherapy and combination therapy By the second quarter of 2019, Skyfall Is expected to launch several clinical trial sites in the United States
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
